Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) | Apply Online

Opportunity Summary:

The Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) opportunity (Funding Opportunity Number PAS-12-122) is a National Institutes of Health program, led through NIDA, designed to push promising substance use disorder (SUD) medication projects further along the development pathway by funding true partnerships rather than single-lab efforts. The central problem the announcement is trying to solve is that medication development is not just a scientific challenge; it is a long, expensive, highly specialized process that typically requires coordinated expertise in areas like preclinical pharmacology and toxicology, formulation, manufacturing, regulatory strategy, clinical trial design and execution, data management, and commercialization planning. Many NIDA-funded investigators can generate strong preclinical candidates but then stall when the project needs the kind of multidisciplinary, real-world drug development experience and sustained resources required to enter and move through clinical testing and ultimately reach the marketplace. This FOA is meant to close that gap by supporting strategic alliances that combine the strengths of two or more organizations working toward a shared medications development goal for SUDs.

Mechanistically, the grant uses the NIH R01 funding mechanism, meaning it supports a defined, research-driven project with a clear plan, milestones, and deliverables aligned with medication development. The emphasis is on leveraging complementary capabilities across partners, such as an academic group with deep disease biology and assay expertise teaming with a clinical organization capable of recruiting and running trials, or a nonprofit or university partnering with a for-profit company that has development, manufacturing, regulatory, or commercialization experience. The overall intent is to help projects transition out of the earlier preclinical phase and avoid getting trapped in the common “valley of death” between laboratory findings and an actual therapeutic product. While the announcement text does not list specific scientific targets in the excerpt you provided, the scope is broadly framed around developing medications to treat substance use disorders, which can include candidate identification and optimization, preclinical development steps needed for an IND-enabling package, and clinical-stage studies that move a candidate closer to eventual approval and adoption.

From an applicant and eligibility standpoint, PAS-12-122 is intentionally broad to encourage cross-sector collaboration. Eligible applicants include small businesses, for-profit organizations (other than small businesses), nonprofits with and without 501(c)(3) status, public and private institutions of higher education, and a wide range of government entities (state, county, city/township, special district governments, independent school districts, and public housing authorities/Indian housing authorities). It also explicitly includes tribal organizations and tribal governments (federally recognized and other than federally recognized), as well as regional organizations. In addition, the eligibility language allows participation by Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs), along with faith-based and community-based organizations and eligible federal agencies. Importantly, non-U.S. entities (foreign institutions) are eligible to apply, non-U.S. components of U.S. organizations may participate, and foreign components are allowable under NIH policy, signaling that NIDA was open to global partnerships where they add essential expertise or capacity.

Financially, the opportunity is a discretionary grant with no cost-sharing or matching requirement, which reduces barriers for applicants that cannot bring significant outside funds to the table. The listed award ceiling is $2,000,000, indicating support can be substantial for a single project, consistent with the reality that serious medication development activities (especially those approaching or entering clinical testing) require meaningful budgets. The program falls under CFDA 93.279 (Drug Abuse and Addiction Research Programs) and is categorized under education and health funding activity areas, reflecting NIH’s public health mission and the translational focus of moving science toward practical treatments.

In terms of timing and status, the opportunity was posted March 21, 2012, and the record shows it was ultimately archived (Archive Date August 18, 2013). The source data also lists multiple dates, including an original closing date of December 4, 2014, and a current closing date of July 18, 2013, which suggests the listing may reflect revisions or an archival action that ended the active application window earlier than the originally planned end date. For anyone looking to pursue something similar now, the most practical takeaway is the program’s model: NIDA was specifically seeking team-based, alliance-driven medication development proposals that combine scientific discovery strength with the operational and regulatory know-how required to move candidates through the clinic and toward real-world use.

For additional official details, the full announcement was hosted through the NIH grants guide at: http://grants.nih.gov/grants/guide/pa-files/PAS-12-122.html, and NIH’s Office of Extramural Research webmaster contact was provided for access or technical issues (FBOWebmaster@OD.NIH.GOV).

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Oil and Gas Development Effects on Mule Deer in North Dakota

Previous opportunity: USDA FNS SNAP Participation 2012

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAS 12 122

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAS 12 122) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAS 12 122", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.